Analysts See $2.67 EPS for Regeneron Pharmaceuticals (REGN), Kcg Holdings Has Increased Panera Bread Co (PNRA) Stake

July 17, 2017 - By mmahotstuff

Kcg Holdings Inc increased Panera Bread Co (PNRA) stake by 176.21% reported in 2016Q4 SEC filing. Kcg Holdings Inc acquired 8,183 shares as Panera Bread Co (PNRA)’s stock rose 35.27%. The Kcg Holdings Inc holds 12,827 shares with $2.63M value, up from 4,644 last quarter. Panera Bread Co now has $7.16 billion valuation. The stock rose 0.03% or $0.08 reaching $314.96 per share. About 232,067 shares traded. Panera Bread Co (NASDAQ:PNRA) has risen 51.10% since July 17, 2016 and is uptrending. It has outperformed by 34.40% the S&P500.

Analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report $2.67 EPS on August, 3 before the open.They anticipate $0.56 EPS change or 26.54% from last quarter’s $2.11 EPS. REGN’s profit would be $283.69 million giving it 46.62 P/E if the $2.67 EPS is correct. After having $2.16 EPS previously, Regeneron Pharmaceuticals Inc’s analysts see 23.61% EPS growth. About 458,609 shares traded. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since July 17, 2016 and is uptrending. It has outperformed by 0.70% the S&P500.

Since February 10, 2017, it had 0 insider buys, and 2 sales for $591,956 activity. Moreton William W. had sold 2,500 shares worth $580,041 on Friday, February 10. The insider Blair Scott G sold 51 shares worth $11,915.

Among 21 analysts covering Panera Bread (NASDAQ:PNRA), 12 have Buy rating, 1 Sell and 8 Hold. Therefore 57% are positive. Panera Bread had 38 analyst reports since July 30, 2015 according to SRatingsIntel. The company was maintained on Friday, February 10 by Telsey Advisory Group. Longbow upgraded Panera Bread Co (NASDAQ:PNRA) on Monday, October 10 to “Buy” rating. RBC Capital Markets downgraded the shares of PNRA in report on Thursday, April 6 to “Sector Perform” rating. The firm earned “Overweight” rating on Tuesday, April 19 by KeyBanc Capital Markets. The rating was upgraded by Maxim Group on Monday, November 23 to “Buy”. The firm earned “Outperform” rating on Wednesday, July 20 by RBC Capital Markets. The rating was upgraded by Goldman Sachs to “Buy” on Thursday, January 19. BTIG Research upgraded the shares of PNRA in report on Wednesday, January 27 to “Buy” rating. The firm has “Outperform” rating by Bernstein given on Thursday, May 26. As per Friday, April 7, the company rating was downgraded by Wells Fargo.

Investors sentiment decreased to 0.73 in 2016 Q4. Its down 0.32, from 1.05 in 2016Q3. It worsened, as 60 investors sold PNRA shares while 126 reduced holdings. 50 funds opened positions while 86 raised stakes. 20.27 million shares or 5.14% less from 21.37 million shares in 2016Q3 were reported. Trillium Asset Mngmt Lc has 104,801 shares for 1.41% of their portfolio. Norris Perne And French Limited Liability Partnership Mi reported 38,052 shares stake. 77,453 are held by Parametric Portfolio Associate Ltd Limited Liability Company. Retirement Of Alabama has 61,994 shares for 0.07% of their portfolio. Argent Capital Limited Liability Corp reported 1,685 shares stake. Waddell & Reed, Kansas-based fund reported 164,100 shares. Blackrock Institutional Tru Com Na reported 0.02% of its portfolio in Panera Bread Co (NASDAQ:PNRA). California State Teachers Retirement System holds 0.02% or 46,489 shares. Calamos Advsrs Ltd holds 130,805 shares. Lba Wealth Mngmt Limited stated it has 0.03% of its portfolio in Panera Bread Co (NASDAQ:PNRA). Moreover, Stevens Management Lp has 0.04% invested in Panera Bread Co (NASDAQ:PNRA) for 4,866 shares. 117,403 were reported by Castleark Lc. Tyvor Ltd Liability Corporation has invested 0.52% in Panera Bread Co (NASDAQ:PNRA). Caldwell Orkin Inc holds 0.64% or 4,900 shares. Fieldpoint Private has invested 2.09% in Panera Bread Co (NASDAQ:PNRA).

Kcg Holdings Inc decreased Powershares Etf Trust (PFI) stake by 24,922 shares to 16,589 valued at $508,000 in 2016Q4. It also reduced Arcelormittal Sa Luxembourg (NYSE:MT) stake by 115,956 shares and now owns 380,288 shares. Recon Cap Ser Tr was reduced too.

Among 26 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 12 have Buy rating, 0 Sell and 14 Hold. Therefore 46% are positive. Regeneron Pharmaceuticals Inc. had 60 analyst reports since July 28, 2015 according to SRatingsIntel. Chardan Capital Markets downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Wednesday, March 16 to “Sell” rating. As per Monday, August 10, the company rating was maintained by TH Capital. UBS maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Wednesday, August 5 with “Sell” rating. Leerink Swann maintained the shares of REGN in report on Monday, June 12 with “Buy” rating. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Sell” rating given on Monday, January 25 by Chardan Capital Markets. On Wednesday, August 5 the stock rating was maintained by Barclays Capital with “Equal Weight”. Brean Capital reinitiated Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Tuesday, March 8 with “Buy” rating. The rating was initiated by Credit Suisse on Wednesday, January 20 with “Neutral”. The stock has “Outperform” rating by Credit Suisse on Tuesday, December 20. The firm earned “Neutral” rating on Monday, December 12 by Chardan Capital Markets.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has market cap of $52.90 billion. The Firm commercializes medicines for eye diseases, high low-density lipoprotein cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. It has a 59.9 P/E ratio. The Company’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>